Skip to main content
. 2016 May 17;7(27):41067–41080. doi: 10.18632/oncotarget.9392

Figure 2. YLL545 inhibits HUVEC proliferation, migration, invasion, and tube formation.

Figure 2

A. Cell viability assays were conducted using HUVECs treated with different concentrations of YLL545. At the indicated time points, cell growth inhibition was determined. **P < 0.01 vs respective control in a one-way ANOVA followed by Tukey's HSD test. B. EdU proliferation assays were conducted using HUVECs treated with different concentrations of YLL545 for 72 h. ***P < 0.001 vs respective control in Student's t-test. Scale bars, 50 μm. C. HUVECs were wounded using pipette tip and then treated with different concentrations of YLL545 or sorafenib for 24 h. Migrated distances were quantified by manual counting and expressed as a percentage of vehicle-treated cell migaration. ***P < 0.001 vs respective control in Student's t-test. Scale bars, 100 μm. D. HUVECs were seeded in the top chamber and treated with different concentrations of YLL545 or sorafenib. After 16 h, HUVECs that migrated through the membrane were stained and quantified. ***P < 0.001 vs respective control in Student's t-test. Scale bars, 100 μm. E. HUVECs were seeded on a Matrigel layer and treated with different concentrations of YLL545 or sorafenib. After 6 h, tubular structures were manually counted. *P < 0.05 and **P < 0.01 vs respective control in Student's t-test. Scale bars, 100 μm.